Markus[a]
March 08, 2005
Inotek Pharmaceuticals Announces Commencement of Enrollment in Phase 1b/2a Trial for Glioblastoma Multiforme
Inotek Pharmaceuticals Corporation announced today that it has commenced enrollment in a Phase 1b/2a trial for its lead compound, INO-1001, in patients with Glioblastoma Multiforme. This study will evaluate tolerability, safety, and pharmacokinetics. This study will also assess pharmacodynamics, including the ability for INO-1001 to transverse the blood brain barrier and to inhibit poly(ADP ribose) polymerase in Glioblastoma Multiforme tumors.
About INO-1001
INO-1001 is a potent inhibitor of poly(ADP ribose) polymerase (PARP). PARP has been widely studied and is believed to be one of the last effectors in the cascade of cell and tissue damage caused by ischemia and reperfusion injury.
Inotek is studying INO-1001 in a variety of scheduled procedures that have a high incidence of complications caused by ischemia and reperfusion injury, including high risk cardiopulmonary bypass surgery, certain aortic aneurysm repair surgeries, and angioplasty after an acute myocardial infarction. Phase 2 trials for these indications are expected to be conducted throughout 2005 and 2006.
Inotek is also studying INO-1001 as a therapy for the treatment of certain late-stage cancers that are refractory to existing chemotherapy. In the first quarter of 2005, Inotek is expecting to commence Phase 1b/2a trials in glioma and stage 4 melanoma patients who have developed resistance to temozolomide.
About Inotek Pharmaceuticals
Inotek Pharmaceuticals is a research-based pharmaceutical company engaged in the discovery and development of novel, small-molecule therapeutics for the treatment of reperfusion injury, inflammation, and vascular dysfunction. The Company has developed a deep and diverse pipeline of products which are based on industry leading expertise in the area of vascular biology and free radical and oxidant mediated mechanisms of tissue injury, cellular necrosis, and inflammation. The Company has one drug product in Phase 2 clinical trials and one other product entering Phase 1 trials in early 2005. Additionally, the Company has five (5) other products that are expected to enter human clinical trials within the next 6-12 months. Inotek´s headquarters and research laboratories are located in Beverly, Massachusetts with overseas clinical operations in Israel.